• 1
    Bishop MC. Experience with low-dose oestrogen in the treatment of advanced prostate cancer: a personal view. Br. J. Urol. 1996; 78: 9218.
  • 2
    Robertson CN, Roberson KM, Padilla GM et al. Induction of apoptosis by diethylstilbestrol in hormone-insensitive prostate cancer cells. J. Natl Cancer Inst. 1996; 88 (13): 90817.
  • 3
    Carruba G, Miceli D, D’Amico D et al. Sex steroids upregulate e-cadharin expression in hormone responsive LNCaP human prostate cancer cells. Biochem. Biophys. Res. Commun. 1995; 212: 62431.
  • 4
    Farrugia D, Ansell W, Singh M, Philp T, Chinegwundoh F, Oliver RT. Stilboestrol plus adrenal suppression as salvage treatment for patients failing treatment with luteinizing hormone-releasing hormone analogues and orchidectomy. Br. J. Urol. Int. 2000; 85: 106973.
  • 5
    Byar DP. The Veterans Administration Cooperative Urological Research Group's studies of cancer of the prostate. Cancer 1973; 32: 112613.
  • 6
    Leuprolide Study Group. Leuprolide versus diethylstilboestrol for metastatic prostate cancer. N. Engl. J. Med. 1984; 311: 12816.
  • 7
    Chang A, Yeap B, Davis T et al. Double-blind, randomised study of primary hormonal treatment of stage D2 prostate carcinoma: flutamide versus diethylstilboestrol. J. Clin. Oncol. 1996; 14 (8): 22507.
  • 8
    Labrie F. Benefits of combination therapy with flutamide in patients relapsing after castration. Br. J. Urol. 1988; 61: 3416.
  • 9
    Fossa SD, Slee PH, Brausi M et al. Flutamide versus prednisone in patients with prostate cancer symptomatically progressing after androgen-ablative therapy: A phase III study of the European Organisation for Research and Treatment of Cancer genitourinary group. J. Clin. Oncol. 2001; 19 (1): 6271.
  • 10
    Kent JR, Bischoff AJ, Arduino LJ et al. Estrogen dosage and suppression of testosterone levels in patients with prostatic carcinoma. J. Urol. 1973; 109: 85860.
  • 11
    Stamey TA, Kabalin JN, Ferrari M, Yang N. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. IV. Anti-androgen treated patients. J. Urol. 1989; 141: 1088.
  • 12
    Miller JI, Ahmann FR, Drach GW, Emerson SS, Bottaccini MR. The clinical usefulness of serum prostate specific antigen after hormonal therapy of metastatic prostate cancer. J. Urol. 1992; 147: 956.
  • 13
    Zanetti G, Trinchieri A, DelNero A et al. Prognostic significance of prostate-specific antigen in endocrine treatment for prostatic carcinoma. Eur. Urol. 1992; 1 (Suppl. 21): 96.